Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas is set to get worldwide manufacturing, development and commercialization rights for Evec's fully-human antibodies targeting infectious diseases.
Subscribe to our email newsletter
Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases.
Astellas will pay a sum of JPY0.6bn as an upfront payment to Evec, under the license agreement.
Further, Astellas will also be responsible to pay milestone payments to Evec depending on development and sales phases totaling up to JPY13bn, as well as royalty payments related to potential product sales.